Ascendis Pharma A/S (NASDAQ:ASND) Hits New 12-Month High – Time to Buy?

Ascendis Pharma A/S (NASDAQ:ASND) hit a new 52-week high on Friday . The company traded as high as $157.40 and last traded at $155.51, with a volume of 179633 shares changing hands. The stock had previously closed at $153.14.

Analysts Set New Price Targets

Several analysts recently weighed in on ASND shares. TD Cowen decreased their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Oppenheimer cut their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. UBS Group began coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. Finally, Cantor Fitzgerald increased their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Trading Up 2.2 %

The company has a 50-day moving average of $136.11 and a 200-day moving average of $133.96. The company has a market capitalization of $9.50 billion, a price-to-earnings ratio of -22.05 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Harbor Capital Advisors Inc. increased its position in shares of Ascendis Pharma A/S by 67.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company’s stock valued at $13,035,000 after acquiring an additional 35,102 shares during the period. Jackson Square Capital LLC acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $1,441,000. Assetmark Inc. acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $331,000. Crossmark Global Holdings Inc. acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $1,212,000. Finally, Oppenheimer Asset Management Inc. increased its holdings in shares of Ascendis Pharma A/S by 10.0% in the third quarter. Oppenheimer Asset Management Inc. now owns 7,622 shares of the biotechnology company’s stock valued at $1,138,000 after purchasing an additional 695 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.